中国临床药学杂志

参考文献

[1]INTERNATIONAL DIABETES FEDERATION.IDF Diabetes Atlas,10th edition[EB/OL].(2021-12-16)[2021-12-16].https://diabetesatlas.org/data/en/indicato rs/1/.

[2]WANG L M,PENG W,ZHAO Z P,et al.Prevalence and treatment of diabetes in China,2013-2018[J].JAMA,2021,326(24):2498.

[3]赵延珍,杜婧.GLP-1受体激动剂治疗2型糖尿病的研究进展[J].老年医学研究,2021,2(3):55.

[4]新型降糖药司美格鲁肽周制剂在华获批,兼顾强效降糖与心血管代谢获益![J].中国循证心血管医学杂志,2021,13(5):636.

[5]SORLI C,HARASHIMA S I,TSOUKAS G M,et al.Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes(SUSTAIN 1):a double-blind,randomised,placebo-controlled,parallel-group,multinational,multicentre phase 3a trial[J].Lancet Diabetes Endocrinol,2017,5(4):251.

[6]FRIAS J P,AUERBACH P,BAJAJ H S,et al.Efficacy and safety of once-weekly semaglutide 2·0 Mg versus 1·0 Mg in patients with type 2 diabetes(SUSTAIN FORTE):a double-blind,randomised.phase 3B trial[J].Lancet Diabetes Endocrinol,2021,9(9):563.

[7]DAVIES M,PIEBER T R,HARTOFT-NIELSEN M L,et al.Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes:a randomized clinical trial[J].JAMA,2017,3 18(15):1460.

[8]ZINMAN B,ARODA V R,BUSE J B,et al.Efficacy,safety,and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes:the PIONEER 8 trial[J].Diabetes Care,2019,42(12):2262.

[9]ANDREADIS P, KARAGIANNIS T,MALANDRIS K,et al.Semaglutide for type 2 diabetes mellitus:a systematic review and meta-analysis[J].Diabetes Obes Metab,2018,20(9):2255.

[10]张晓昕,张卫东.口服索马鲁肽治疗2型糖尿病的临床评估[J].健康必读,2021(7):77.

[11]秦元,周俊凝,张春燕,等.索马鲁肽治疗2型糖尿病疗效与安全性的系统评价[J].沈阳药科大学学报,2019,36(7):626.

[12]JI L N,DONG X L,LI Y M,et al.Efficacy and safety of onceweekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China:a30-week,double-blind,phase 3a,randomized trial[J].Diabetes Obes Metab,2021,23(2):404.

[13]PIEBER T R,BODE B,MERTENS A,et al.Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes(PIONEER 7):a multicentre,open-labe1,randomised,phase 3a trial[J].Lancet Diabetes Endocrinol,2019,7(7):528.

[14]BUSE J B,BODE B W,MERTENS A,et al.Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes:a52-weeks randomized,open-label extension of the PIONEER 7 trial[J].BMJ Open Diabetes Res Care,2020,8(2):e001649.

[15]KANTERS S,WILKINSON L,VRAZIC H,et al.Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs:a systematic literature review and network meta-analysis[J].BMJ Open,2019,9(7):e023458.

[16]LINGVAY I,CAPEHORN M S,CATARIG A M,et al.Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes:patient-level meta-analysis[J].J Clin Endocrinol Metab,2020,105(12):dgaa577.

[17]AHMANN A J,CAPEHORN M,CHARPENTIER G,et al.Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes(SUSTAIN 3):a 56-week,open-label,randomized clinical trial[J].Diabetes Care,2018,41(2):258.

[18]LINGVAY I,DESOUZA C V,LALIC K S,et al.A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin[J].Diabetes Care,2018,41(9):1926.

[19]CAPEHORN M S,CATARIG A M,FURBERG J K,et al.Efficacy and safety of once-weekly semaglutide 1.Omg vs oncedaily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes(SUSTAIN 10)[J].Diabetes Metab,2020,46(2):100.

[20]PRATLEY R,AMOD A,HOFF S T,et al.Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes(PIONEER4):a randomised,double-blind,phase 3a trial[J].Lancet,2019,394(10192):39.

[21]YAMADA Y,KATAGIRI H,HAMAMOTO Y,et al.Dose-response,efficacy,and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes(PIONEER 9):a 52-week,phase 2/3a,randomised,controlled trial[J].Lancet Diabetes Endocrinol,2020,8(5):377.

[22]PRATLEY R E,ARODA V R,LINGVAY I,et al.Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes(SUSTAIN 7):a randomised,open-label,phase 3b trial[J].Lancet Diabetes Endocrinol,2018,6(4):275.

[23]XIA L,SHEN T T,DONG W L,et al.Comparative efficacy and safety of 8 GLP-IRAs in patients with type 2 diabetes:a network meta-analysis[J].Diabetes Res Clin Pract,2021,177:108904.

[24]中华医学会内分泌学分会,中国药学会医院药学专业委员会.《基于肠促胰素的药物治疗临床应用的快速建议指南》[J].糖尿病天地(临床),2016,10(1):6.

[25]RODBARD H W,LINGVAY I,REED J,et al.Semaglutide added to basal insulin in type 2 diabetes(SUSTAIN 5):a randomized,controlled trial[J].J Clin Endocrinol Metab,2018,103(6):2291.

[26]ZINMAN B,BHOSEKAR V,BUSCH R,et al.Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes(SUSTAIN 9):a randomised,placebo-controlled trial[J].Lancet Diabetes Endocrinol,2019,7(5):356.

[27]ARODA V R,BAIN S C,CARIOU B,et al.Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as addon to metformin(with or without sulfonylureas)in insulin-naive patients with type 2 diabetes(SUSTAIN 4):a randomised,openlabel,parallel-group,multicentre,multinational,phase 3a trial[J].Lancet Diabetes Endocrinol,2017,5(5):355.

[28]LINGVAY I,CATARIG A M,FRIAS J P,et al.Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes(SUSTAIN 8):a doubleblind,phase 3b,randomised controlled trial[J].Lancet Diabetes Endocrinol,2019,7(11):834.

[29]LI J X,HE K,GE J,et al.Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type2 diabetes mellitus:a systematic review and meta-analysis[J].Diabetes Res Clin Pract,2021,172:108656.

[30]李梦雅,钟小燕,刘鑫,等.口服索马鲁肽治疗2型糖尿病有效性和安全性的Meta分析[J].中国新药与临床杂志,2020,39(6):367.

[31]杨婷,李明莎,王治坤.皮下注射索马鲁肽治疗2型糖尿病有效性和安全性的Meta分析[J].中国药房,2018,29(20):2856.

[32]芦志伟,孙浩,李莹,等.长效GLP-1受体激动药索马鲁肽治疗2型糖尿病疗效和安全性的系统评价[J].中国药房,2019,30(7):969

[33]覃渝,左丹妮,高倩,等.口服索马鲁肽治疗2型糖尿病疗效和安全性的系统评价[J].中国药房,2020,31(19):2399.

[34]AVGERINOS I,MICHAILIDIS T,LIAKOS A,et al.Oral semaglutide for type 2 diabetes:a systematic review and metaanalysis[J].Diabetes Obes Metab,2020,22(3):335.

[35]GRANHALL C,DONSMARK M,BLICHER T M,et al.Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue,oral semaglutide,in healthy subjects and subjects with type 2 diabetes[J].Clin Pharmacokinet,2019,58(6):781.

[36]SHI A X,XIE P P,NIELSEN L L,et al.Pharmacokinetics,safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects:a double-blind,phaseⅠ,randomized controlled trial[J].Adv Ther,2021,38(1):550.

[37]朱翊,封宇飞.GLP-1受体激动剂索马鲁肽的药理与临床评价[J].临床药物治疗杂志,2018,16(3):17.

[38]KORSATKO S,JENSEN L,BRUNNER M,et al.Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes:a randomized,placebo-controlled,double-blind,crossover trial[J].Diabetes Obes Metab,2018,20(11):2565.

[39]安文成,魏蕊,洪天配.胰高血糖素样肽1类药物对糖尿病肾病的保护作用及潜在机制[J].中华医学杂志,2017,97(42):3354.

[40]HUSAIN M,BIRKENFELD A L,DONSMARK M,et al.Oral semaglutide and cardiovascular outcomes in patients with type 2diabetes[J].N Engl J Med,2019,381(9):841.

[41]MOSENZON O,BLICHER T M,ROSENLUND S,et al.Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment(PIONEER 5):a placebo-controlled,randomised,phase 3a trial[J].Lancet Diabetes Endocrinol,2019,7(7):515.

[42]MANN J F E, HANSEN T,IDORN T,et al.Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patientswith type 2 diabetes:a post-hoc analysis of the SUSTAIN 1-7randomised controlled trials[J].Lancet Diabetes Endocrinol,2 0 2 0,8(11):88 0.

[43]MARBURY T C,FLINT A,JACOB SEN J B,et al.Pharmacokinetics and tolerability of a single dose of semaglutide,a human glucagon-like peptide-1 analog,in subjects with and without renal impairment[J].Clin Pharmacokinet,2017,56(11):1381.

[44]GRANHALL C, S?NDERGAARD F L,THOMSEN M,et al.Pharmacokinetics,safety and tolerability of oral semaglutide in subjects with renal impairment[J].Clin Pharmacokinet,2018,57(12):1571.

[45]VERMA S,BAIN S C,HONORE J B,et al.Impact of microvascular disease on cardiovascular outcomes in type 2diabetes:results from the LEADER and SUSTAIN 6 clinical trials[J].Diabetes Obes Metab,2020,22(11):2193.

[46]HUSAIN M,BIRKENFELD A L,DONSMARK M,et al.Oral semaglutide and cardiovascular outcomes in patients with type 2diabetes[J].N Engl J Med,2019,381(9):841.

[47]BAIN S C,MOSENZON O,ARECHAVALETA R,et al.Cardiovascular safety of oral semaglutide in patients with type 2diabetes:Rationale,design and patient baseline characteristics for the PIONEER 6 trial[J].Diabetes Obes Metab,2019,21(3):499.

[48]ALFAYEZ O M,ALMOHAMMED O A,ALKHEZI O S,et al.Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus:network meta-analysis[J].Cardiovasc Diabetol,2020,19(1):96.

[49]付平,汤蕾.新型降糖药在2型糖尿病合并慢性肾脏病患者中的临床应用及卫生经济学评价[J].西部医学,2021,33(2):157.

[50]RAMOS M,CUMMINGS M H,USTYUGOVA A,et al.Longterm cost-effectiveness analyses of empagliflozin versus oral semaglutide,in addition to metformin,for the treatment of type 2diabetes in the UK[J].Diabetes Ther,2020,11(9):2041.

[51]BAIN S C,HANSEN B B,MALKIN S J P,et al.Oral semaglutide versus empagliflozin,sitagliptin and liraglutide in the UK:longterm cost-effectiveness analyses based on the PIONEER clinical trial programme[J].Diabetes Ther,2020,11(1):259.

[52]MARTIN V,VIDAL J,MALKIN S J P,et al.Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting[J].Adv Ther,2020,37(10):4427.

[53]JENDLE J, BIRKENFELD A L,POLONSKY W H,et al.Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials[J].Diabetes Obes Metab,2019,21(10):2315.

[54]SNITKER S,ANDERSEN A,BERG B,et al.Comparison of theinjection-site experience of the starting doses with semaglutide and dulaglutide:a randomized,double-blind trial in healthy subjects[J].Diabetes Obes Metab,2021,23(6):1415.

[55]WARREN M, CHAYKIN L,TRACHTENBARG D,et al.Semaglutide as a therapeutic option for elderly patients with type 2 diabetes:Pooled analysis of the SUSTAIN 1-5 trials[J].Diabetes Obes Metab,2018,20(9):2291.

[56]DOGGRELL S A.Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?[J].Expert Opin Biol Ther,2020,20(5):489.

[57]WILDING J P H,BATTERHAM R L,CALANNA S,et al.Onceweekly semaglutide in adults with overweight or obesity[J].N Engl J Med,2021,384(11):989.

[58]DAVIES M,F?RCH L,JEPPESEN O K,et al.Semaglutide 2·4Mg once a week in adults with overweight or obesity,and type 2diabetes(STEP 2):a randomised,double-blind,double-dummy,placebo-controlled,phase 3 trial[J].Lancet,2021,397(10278):971.

[59]JENSTERLE M,FERJAN S,VOVK A,et al.Semaglutide reduces fat accumulation in the tongue:a randomized single-blind,pilot study[J].Diabetes Res Clin Pract,2021,178:108935.

[60]NEWSOME P N,BUCHHOLTZ K,CUSI K,et al.A placebocontrolled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J].N Engl J Med,2021,384(12):1113.

[61]药物临床试验登记与信息公示平台.一项研究Semaglutide用于早期阿尔茨海默病患者的试验性研究(EVOKE plus)[EB/OL].(2021-11-09)[2022-01-03].http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml.

[62]LAU J, BLOCH P,SCH?FFER L,et al.Discovery of the onceweekly glucagon-like peptide-1(GLP-1)analogue seoaglutide[J].J Med Chem, 2015,58(18):7370.

[63]BUCKLEY S T,BIEKDAL T A,VEGGE A,et al.Transcellular stomach absorption of a derivatized glucagon-like peptide-1receptor agonist[J].Sci Transl Med,2018,10(467):eaar7047.

[64]MEIER J J.Efficacy of semaglutide in a subcutaneous and an oral formulation[J].Front Endocrinol(Lausanne),2021,12:645617.

[65]DAVIES M,PIEBER T R,HARTOFT-NIELSEN M L,et al.Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes:a randomized clinical trial[J].JAMA,2017,318(15):1460.

[66]国家医保局.国家医保局人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2021年)》的通知[EB/OL].(2021-12-03)[2022-01-15].http://www.nhsa.gov.cn/art/2021/12/3/art_37_7429.html.